Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

2,201

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

March 13, 2025

Study Completion Date

February 15, 2035

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Ticagrelor 90mg twice daily and ASA 75-100 mg daily

Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome

DRUG

ASA 75-160 mg daily

Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome

Trial Locations (22)

Unknown

Aalborg University Hospital, Aalborg

Aarhus University Hospital, Aarhus

Rigshospitalet, Copenhagen

Odense University Hospital, Odense

Helsinki University Hospital, Helsinki

Kuopio University Hospital, Kuopio

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Landspítali University Hospital, Reykjavik

St. Olavs hospital, University Hospital, Bergen

Oslo University Hospital, Oslo

University Hospital of North Norway, Tromsø

Haukeland University Hospital, Trondheim

Sahlgrenska University Hospital, Gothenburg

Blekinge Hospital, Karlskrona

Linköping University Hospital, Linköping

Skåne University Hospital, Lund

Örebro University Hospital, Örebro

Karolinska University Hospital, Stockholm

University Hospital of Umeå, Umeå

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Gothia Forum - Center for Clinical Trial

OTHER

collaborator

Göteborg University

OTHER

lead

Vastra Gotaland Region

OTHER_GOV